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Feline leukemia virus (FeLV), like other naturally occurring retroviruses, is characterized by a high degree of genetic
diversity. FeLV-945 is a natural isolate derived from non-B-cell non-T-cell lymphomas classified anatomically as multicentric.
FeLV-945 exhibits a unique structural motif in the LTR composed of a 21-bp tandem triplication downstream of a single copy
of enhancer. The unique FeLV-945 LTR is precisely conserved among eight independent multicentric lymphomas collected
in a geographic cluster. Previous studies using reporter gene constructs predict that the FeLV-945 LTR would confer a
replicative advantage on the virus that contains it, particularly in primitive hematopoietic cells. Such an advantage may
account for the precise conservation of the unique LTR sequence. To test that prediction, a set of recombinant, infectious
FeLVs was developed that are isogenic other than the presence of the FeLV-945 LTR or mutations of it. Replication assays
show that the FeLV-945 LTR confers a distinct growth advantage in K-562, FEA, and 3201 cells and implicate the 21-bp
triplication in that function. Replacement of two copies of the triplicated element with random sequence greatly diminished
the replicative capacity, thus implicating the triplicated sequence itself in LTR function. The 21-bp triplication was shown to
contain specific nuclear protein binding sites, which may account for the selective pressure to conserve the sequence.
© 1999 Academic Press
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Retroviruses, like other viruses with RNA genomes,
enerally do not consist of a single genomic species of
efined sequence. Rather the RNA virus population in
he natural host can be more accurately described as a
ixture of closely related genomes, termed a quasispe-
ies or swarm. During infection in the natural host, the
irus population is continually shaped by selective
orces. The variable genomic structure of natural RNA
irus populations is thought to have significant biological
mpact because mutations at only a small number of
ites may alter the virus phenotype. Such alterations
rovide the substrate on which selective pressures act to
hape the population (Domingo et al., 1985; Katz and
kalka, 1990; Coffin, 1992; Mansky, 1998).
Natural retrovirus populations, in particular, are char-
cterized by a high degree of genetic diversity. Variant
enomes are generated at a high rate during retrovirus
eplication because of both error-prone reverse tran-
cription and recombination (Katz and Skalka, 1990; Cof-
in, 1992; Mansky, 1998). These mechanisms generate
enetic variability in natural retrovirus populations, upon
hich selective forces act to promote the conservation
and sometimes the predominance) of variants with an
1 To whom reprint requests should be addressed. Fax: (504) 588-
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460dvantageous phenotype (Katz and Skalka, 1990; Coffin,
992; Mansky, 1998). A number of investigators have
onsidered aspects of retrovirus phenotype that may be
ubject to selective pressure during infection in vivo
reviewed in Katz and Skalka, 1990; Coffin, 1992; Mansky,
998). A replicative advantage, for example, may be re-
lized as increased levels of virus in infected tissues or
ncreased kinetics of virus spread. Indeed, it is clear that
replicative advantage does not have to be large to have
n impact on retrovirus population dynamics. For exam-
le, it has been calculated that a mutation which affords
1% replication advantage will represent 50% of the
irus population within 400 replication cycles, assuming
mutation rate of 1024 (Coffin, 1992). Alternatively, a
utation may decrease replication, thus prolonging sur-
ival of the host. It is further hypothesized that pheno-
ypic advantage may not be replicative at all. For exam-
le, a mutation may afford a selective advantage if it
romotes survival of the infected cell, e.g., through inser-
ional activation of proto-oncogenes.
Feline leukemia virus (FeLV) is a naturally occurring
etrovirus endemic in an outbreeding mammalian spe-
ies, the domestic cat. In this respect, FeLV infection in
ts natural host emulates human infections more closely
han does retroviral infection in laboratory inbred ani-
als. In fact, FeLV in cats has been widely used as a
odel to study population dynamics in host–parasitenteractions (Courchamp et al., 1997; Fromont et al.,
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461FUNCTION OF THE UNIQUE FeLV-945 LTR998). Like other retroviruses, FeLV is a genetically com-
lex family of closely related viruses subject to selective
ressures in the natural host, although the selective
dvantages conferred by natural variants are not well
nderstood. The variable clinical outcome of FeLV infec-
ion, thought to reflect its genetic diversity, includes de-
enerative diseases like anemia or immunodeficiency as
ell as proliferative diseases like leukemia and lym-
homa (Hoover and Mullins, 1991; Neil et al., 1991;
ezanka et al., 1992). Molecular analysis of FeLV in
atural infections indicates that genetic variations,
ometimes minor, may have significant impact on virus
henotype and pathogenesis. Genetic variations most
learly linked to phenotypic change generally occur
ithin the surface glycoprotein gene (SU) or the viral long
erminal repeat (LTR) (Hoover and Mullins, 1991; Neil et
l., 1991).
The LTR of FeLV is similar in structure to that of the
urine leukemia viruses (MuLV) and contains a central
nhancer motif that is strongly conserved, structurally
nd functionally, among mammalian C-type retroviruses
Golemis et al., 1990; Pantginis et al., 1997). The basic
nhancer motif contains a tandem series of binding sites
or the nuclear factors LVb/Ets, core enhancer binding
rotein, nuclear factor 1 (NF-1), and a glucocorticoid
esponse element (Fulton et al., 1990; Neil et al., 1991;
thas et al., 1994). It is noteworthy that the typical FeLV
solate horizontally transmitted among animals in nature
ontains only a single copy of the enhancer. In contrast,
eLV proviruses cloned directly from thymic lymphomas
ypically contain tandemly repeated enhancers, gener-
lly in two or three directly repeated copies. The specific
nhancer duplication is unique to each isolate but invari-
bly includes a 35-bp domain containing the core bind-
ng site (Fulton et al., 1990; Plumb et al., 1991; Matsumoto
t al., 1992; Nishigaki et al., 1997). Analysis of experimen-
al infection with single enhancer-containing virus dem-
nstrates that duplicated enhancers in the FeLV LTR are
enerated in vivo during passage in a single animal and
redominate in thymic lymphomas (Rohn and Over-
augh, 1995). By comparison, an FeLV variant termed
eLV-945 exhibits a structure unique among FeLV iso-
ates. The LTR of FeLV-945 is unique in two respects: (1)
t contains only a single copy of enhancer, unusual for
umor-derived proviruses, and (2) it contains a tandem
1-bp triplication beginning ;25-bp downstream of the
nhancer (Levesque et al., 1990; Athas et al., 1995a).
eLV-945 was identified in natural lymphomas classified
natomically as multicentric. Such tumors typically in-
olve lymph nodes, spleen, liver, and kidneys, alone or in
ny combination, but generally not the thymus (Rezanka
t al., 1992). Multicentric lymphomas in our collection are
f non-T-cell non-B-cell origin, unlike the more common
hymic tumors of T-cell origin. Although their precise
ineage and differentiation state remain unknown, they
re thought to represent a lymphoid or other hematopoi- ttic progenitor (Athas et al., 1995a). It is striking that the
equence and position of the 21-bp triplication are pre-
isely conserved among FeLV-945 LTRs identified in 8 of
1 independent multicentric lymphomas collected in a
eographic cluster (Athas et al., 1995a,b).
Previous studies have been performed to explore the
ossible role of the 21-bp triplication in the FeLV-945 LTR
nd the potential selective advantages that may account
or its precise conservation. In particular, the ability of the
eLV-945 LTR to modulate reporter gene expression has
een compared to that of two other naturally occurring
eLV isolates. The results indicated that the 21-bp tripli-
ation provides transcriptional enhancer function to the
TR that contains it and that it functions preferentially in
rimitive hematopoietic cells (Athas et al., 1995b). In
-562 cells, a human leukemia cell line considered to be
rimitive and multipotential (Lozzio et al., 1981; Burger et
l., 1992), the FeLV-945 LTR was shown to be as much as
2-fold more active than other naturally occurring FeLV
TRs examined. Further, the FeLV-945 LTR was shown to
e more active in K-562 than in other cells examined. For
xample, the level of activity of the triplication-containing
TR in K-562 cells was 4.2-fold higher than its activity in
EA cells, a feline embryo fibroblast cell line (Athas et al.,
995b). A prediction of these findings is that the FeLV-945
TR confers a replicative advantage on the virus that
ontains it, especially in primitive hematopoietic cells.
his growth advantage may account for the induction of
umors of the type in which FeLV-945 was identified and
ay represent a selective advantage that contributes to
ts precise conservation. The experiments reported be-
ow were designed to test the prediction that the FeLV-
45 LTR confers a replicative advantage and to explore
he molecular mechanism of its influence.
RESULTS AND DISCUSSION
A prediction of the findings from previous studies
Athas et al., 1995b) is that the FeLV-945 LTR would
onfer a growth advantage on the virus that contains it,
specially in primitive hematopoietic cells. To test that
rediction, a set of recombinant, infectious FeLVs was
eveloped based on the genome of FeLV-B/Gardner-
rnstein [FeLV-B/GA (Mullins et al., 1981)]. FeLV-B/GA
as chosen for this purpose because members of FeLV
ubtype B are infectious to human cells; thus, recombi-
ants based on FeLV-B/GA could be used to infect hu-
an K-562 as a model for primitive hematopoietic cells.
hree recombinant, infectious FeLVs were constructed
Fig. 1): GA-945L contains the FeLV-945 LTR (Athas et al.,
995a), substituted into FeLV-B/GA between conserved
coRV and KpnI restriction sites. GA-922L contains an
coRV–HincII fragment of the FeLV-922 LTR (Athas et al.,
995a), substituted into GA-945L. GA-922L is isogenic
ith GA-945L except that it contains only a single copy ofhe 21-bp sequence. GA-61EL contains an EcoRV–HincII
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462 PRABHU, LOBELLE-RICH, AND LEVYragment of the FeLV-A/61E LTR (Donahue et al., 1988),
ubstituted into GA-945L. GA-61EL differs from GA-945L
n that the LTR contains only a single copy of the 21-bp
equence, in which a nucleotide substitution occurs at
osition 11 (“A” in GA-945L, “G” in GA-61EL). The FeLV-
/61E LTR also differs at two other nucleotides, both of
hich are located between the enhancer and the 21-bp
riplication. FeLV-A/61E was selected for examination
ecause it represents a naturally occurring isolate of
eLV typical of those horizontally transmitted among cats
n nature (Donahue et al., 1988).
Infectious virus stocks were developed by electropo-
ation of plasmid DNA encoding each recombinant pro-
irus into canine D-17 cells. D-17 cells were chosen to
void the risk of recombination with endogenous FeLV-
elated sequences present in feline, but not canine, cells
Roy-Burman, 1996). Productive infection was docu-
ented by ELISA for FeLV p27gag in culture superna-
ants (Synbiotics Corp.). Culture supernatants were col-
ected at Day 7 after electroporation and were frozen in
liquots at 270°C. Infectious titer of each stock was
etermined by end-point dilution in triplicate on D-17
ells. Infectious titers thus determined were 9 3 105/ml,
.5 3 105/ml, and 1.9 3 106/ml for GA-945L, GA-922L, and
A-61EL, respectively. Integrity of the recombinant LTR
equence in producer D-17 cells was verified by RT–PCR
mplification and nucleotide sequence analysis. Specif-
cally, total cellular RNA was isolated from each producer
ell line, reverse transcribed, and amplified by PCR using
rimers specific for the U3 region of the FeLV LTR (Fig. 1).
FIG. 1. Diagram of the LTR of recombinant FeLVs constructed on the g
equence, and the positioning of those elements relative to the promote
equence. GA-922L and GA-61EL differ as indicated at nucleotide 11 o
nhancer and the 21-bp sequence (not shown). Shown are EcoRV, Hin
hown are the positions of oligonucleotide primers LTR13 and LTR14 ugarose gel electrophoresis of the results demonstrated Gmplification of a single product of the predicted size in
ach case. Subsequent cloning and nucleotide se-
uence analysis demonstrated each recombinant U3 re-
ion to be intact and unaltered in producer D17 cells
data not shown).
To test the prediction that the FeLV-945 LTR confers a
rowth advantage on the virus that contains it, parallel
ultures of K-562 cells were infected with equivalent
mounts of GA-945L, GA-922L, or GA-61EL. Specifically,
3 106 K-562 cells, at a density of 2 3 105 cells/ml, were
ncubated with recombinant virus at m.o.i. 5 0.001 for 5 h
n culture medium with Polybrene added at 8 mg/ml.
ulture supernatants were harvested periodically there-
fter for assay of reverse transcriptase activity. At each
ollection, 4 3 106 cells were reseeded at 2 3 105
ells/ml to maintain a relatively constant cell density
hroughout the experiment. Cells remaining after reseed-
ng also were frozen at each time point for isolation of
NA. The entire experiment was performed in triplicate
ith each recombinant virus. To assay the reverse tran-
criptase activity in culture supernatants collected at
ach time point, virus was pelleted by ultracentrifugation
nd resuspended for analysis, and at least three serial
ilutions of the suspension were analyzed to ensure that
ata were collected in the linear range of the assay. The
esults showed that the triplication-containing FeLV-945
TR, as present in GA-945L, confers a distinct growth
dvantage in K-562 cells (Fig. 2A). At Days 7–11, for
xample, cells infected with GA-945L are producing from
ive- to eightfold more virus than cells infected with
of FeLV-B/GA. Indicated are the number of repeats of enhancer, 21-bp
GA-945L is isogenic with GA-922L except for the triplication of a 21-bp
-bp sequence and also at two other nucleotides located between the
KpnI restriction sites used in construction of the recombinants. Also
CR to amplify products of the indicated sizes from recombinant LTRs.enome
r (Pro).
f the 21
cII, andA-922L or GA-61EL. By Day 21, however, equivalent
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463FUNCTION OF THE UNIQUE FeLV-945 LTRumbers of particles are produced. This finding likely
eflects the maximal capacity of the culture to produce
eLV once all cells are infected and are maximally pro-
ucing virus. Thus the replicative advantage conferred
y the triplication-containing LTR is seen in the kinetics
f virus spread. During the course of the experiment,
ellular RNA also was isolated from infected cells col-
ected at each time point. Northern blot analysis of viral
NA expressed in infected cells also demonstrated the
rowth advantage conferred by the FeLV-945 LTR in
-562 cells, thus confirming the finding by an indepen-
ent measure (Fig. 2B). These findings are consistent
ith previous studies using reporter gene constructs,
hich showed that the triplication-containing FeLV-945
FIG. 2. Replication kinetics of GA-945L, GA-922L, and GA-61EL in
everse transcriptase activity in culture supernatants. Culture supernat
everse transcriptase activity was measured on 3–4 serial dilutions of e
he experiment was repeated three times independently. The data show
s cpm/ml of [3H]-TTP incorporated. (B) Northern blot analysis of RNA
NA was isolated from infected cells periodically after infection and wa
or exogenous FeLV U3 (vRNA). As a loading control, blots were rehybTR functions in K-562 cells to a level approximately an mrder of magnitude higher than the FeLV/A-61E LTR
Athas et al., 1995b). As described above (Fig. 1), a
aturally occurring polymorphism occurs at nucleotide
1 of the 21-bp sequence (“A” in GA-945L and GA-922L,
G” in GA-61EL). This polymorphism appears not to im-
act the replication kinetics of the virus because GA-922
nd GA-61E are indistinguishable in this assay.
A similar experiment then was performed using feline
ibroblasts (FEA), a cell line in which reporter gene as-
ays had previously indicated the function of the FeLV-
45 LTR to be 2.6-fold higher than that of FeLV-A/61E
Athas et al., 1995b). In this experiment, 1 3 106 adherent
EA cells were incubated with each recombinant virus at
.o.i. 5 0.001 for 5 h in the presence of Polybrene at 8
ells. (A) Replication kinetics of recombinant FeLVs, as measured by
ere collected at 2, 4, 7, 9, 11, and 21 days after infection as indicated.
ple, to ensure that data were collected in the linear range of the assay.
sent the mean and standard error of triplicate experiments, expressed
-562 cells infected with GA-945L, GA-922L, or GA-61EL. Total cellular
ined by Northern blot hybridization (Bonham et al., 1987) with a probe
to a probe for b-actin.K-562 c
ants w
ach sam
n repre
from K
s examg/ml. Culture supernatants were harvested periodically
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464 PRABHU, LOBELLE-RICH, AND LEVYhereafter for assay of reverse transcriptase activity. At
ach collection, 1 3 106 cells were reseeded to maintain
relatively constant cell density throughout the experi-
ent. The entire experiment was performed in triplicate
ith each recombinant virus. Analysis of reverse tran-
criptase activity in culture supernatants demonstrated
hat the FeLV-945 LTR, as represented in GA-945L, con-
ers a 3-fold growth advantage in FEA cells (Fig. 3A). This
dvantage is evident as early as Day 6 p.i. and remains
hroughout the exponentially increasing period of virus
pread (through Day 12). Northern blot analysis of viral
NA expressed in infected FEA confirms the growth
dvantage conferred by the FeLV-945 LTR (Fig. 3B). The
esults of these experiments in K-562 and FEA cells are
onsistent with reporter gene assays performed previ-
usly (Athas et al., 1995b). The studies indicate that the
FIG. 3. Replication kinetics of GA-945L, GA-922L, and GA-61EL in FEA
ranscriptase activity in culture supernatants. Culture supernatants we
ranscriptase activity in culture supernatants was measured as describ
rror of triplicate experiments, expressed as cpm/ml of [3H]-TTP incorpo
A-922L, or GA-61EL. Total cellular RNA was isolated from infected cell
Bonham et al., 1987) with a probe for exogenous FeLV U3 (vRNA). Asriplication-containing FeLV-945 LTR confers a growth idvantage on the virus that contains it and that the
dvantage is greatest in primitive hematopoietic cells.
In contrast, when the experiment was performed using
urkat T cells, no growth advantage conferred by the
eLV-945 LTR was detected. Rather, all recombinant
eLVs examined replicated to comparable levels in Jur-
at T-cells (data not shown). These findings are incon-
istent with previous studies using reporter gene con-
tructs in Jurkat cells, in which the activity of the FeLV-
45 LTR was 2-fold higher than that of FeLV-A/61E (Athas
t al., 1995b). A problem in interpreting the present find-
ngs, however, is that FeLV replicates very poorly in
urkat cells. For example, reverse transcriptase assay of
urkat cell supernatants collected at 21 days p.i. reveals
nly 4.8 3 103 cpm/ml [3H]-TTP incorporated, compared
o 2.1 3 106 cpm/ml in the same assay performed with
(A) Replication kinetics of recombinant FeLVs, as measured by reverse
ected at 3, 6, 9, 12, and 26 days after infection as indicated. Reverse
e legend to Fig. 2. The data shown represent the mean and standard
B) Northern blot analysis of RNA from FEA cells infected with GA-945L,
dically after infection and was examined by Northern blot hybridization
ing control, blots were rehybridized to a probe for b-actin.cells.
re coll
ed in th
rated. (
s perionfected K-562 cells. Thus the restriction on FeLV repli-
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465FUNCTION OF THE UNIQUE FeLV-945 LTRation in Jurkat cells may obscure any differences in
eplicative potential of the recombinant viruses. The
ame experiment performed using MOLT-4, another hu-
an leukemia cell line of T-lymphoid origin, revealed a
imilar restriction on FeLV replication (data not shown).
herefore to explore the potential replicative advantage
onferred by the FeLV-945 LTR in T-cells, feline 3201
-cells were used. Previous studies by others have
hown that 3201 cells are resistant to infection with FeLV
ubtype B (Boomer et al., 1994) probably because these
ells express a defective endogenous FeLV envelope
rotein that blocks exogenous FeLV-B infection (McDou-
all et al., 1994). For this reason, our recombinant viruses
ased on FeLV-B/GA could not be used to examine
eplication in 3201 cells. Rather we used a plasmid
ncoding FeLV-A/61E (Donahue et al., 1988) and a pre-
iously described recombinant termed 61g945L, in which
he LTR of FeLV-A/61E was substituted with that of FeLV-
45 (Athas et al., 1995b). Plasmid DNA (4 mg) encoding
eLV-A/61E or 61g945L was introduced by liposome-
ediated transfection into 4 3 106 3201 T-cells growing
t a density of 2 3 105 cells/ml. Culture supernatants
ere harvested periodically thereafter for assay of re-
erse transcriptase activity. At each collection, 4 3 106
ells were reseeded at 2 3 105 cells/ml to maintain a
elatively constant cell density throughout the experi-
ent, and the entire experiment was repeated in tripli-
ate for each virus. Analysis of reverse transcriptase
ctivity in culture supernatants revealed that the FeLV-
45 LTR, when substituted into FeLV-A/61E, confers a
FIG. 4. Replication kinetics of FeLV-A/61E and 61g945L in 3201 T-c
ulture supernatants were collected at 4, 7, 12, 18, 21, and 25 days afte
as measured as described in the legend to Fig. 2. The data shown re
pm/ml of [3H]-TTP incorporated.istinct growth advantage in 3201 T-cells (Fig. 4). At Day b2, for example, reverse transcriptase activity in super-
atants of 61g945L-infected cells is 13-fold higher than in
eLV-A/61E-infected cells (6.5 3 104 cpm/ml vs 5 3 103
pm/ml). By Day 18, reverse transcriptase activity in su-
ernatants of 61g945L-infected cells exceeds 106 cpm/
l, a level not reached by FeLV-A/61E-infected cells until
ay 25.
These data show that the FeLV-945 LTR confers a
rowth advantage on the virus that contains it, especially
n multipotential hematopoietic cells and in feline T-cells.
ecause GA-945 and GA-922 are isogenic viruses other
han the presence or absence of the 21-bp triplication, a
omparison of their replication kinetics directly impli-
ates the 21-bp triplication in the function of the FeLV-945
TR. Regarding the molecular mechanism by which the
1-bp triplication may function in the context of the FeLV-
45 LTR, at least two possibilities have been considered.
ne possibility is that the triplication contributes genuine
nhancer function, perhaps via the binding of nuclear
ranscription factors. An alternative possibility is that the
1-bp triplication functions to maintain the appropriate
pacing in the LTR between the enhancer and the pro-
oter. A spacer function might be particularly relevant in
n LTR, like the triplication-containing LTR, in which the
nhancer is not tandemly repeated. It is possible that
oth functions may be served, as is apparently the case
ith the region termed DEN of the MCF13 LTR (Chen and
oshimura, 1994, 1998; Yoshimura et al., 1997). It is note-
orthy that the 42-bp contributed by two additional cop-
es of the 21-bp repeat represent an exact multiple of 10.5
measured by reverse transcriptase activity in culture supernatants.
on as indicated. Reverse transcriptase activity in culture supernatants
t the mean and standard error of triplicate experiments, expressed asells, as
r infecti
presenp per helical turn of DNA, i.e., four whole turns (Rhodes
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466 PRABHU, LOBELLE-RICH, AND LEVYnd Klug, 1980; Tullius and Dombroski, 1985). The ste-
eospecific alignment provided by the triplication could
e contributory to enhancer and/or spacer functions as
onsidered recently by others studying the MCF MuLV
TR (Chen and Yoshimura, 1998; DiFronzo and Holland,
999).
To investigate the mechanism by which the 21-bp tripli-
ation influences LTR function, studies were previously
erformed in which the spacing of LTR elements was dis-
upted, and the function of such LTRs was examined in
eporter gene constructs. Specifically, a restriction fragment
ontaining the enhancer and the 21-bp triplication of the
eLV-945 LTR was removed from its position upstream of
he transcriptional promoter and cloned downstream of the
eporter gene. An analogous construct was prepared from
he LTR of FeLV-A/61E. Reporter gene assays performed in
-562 cells showed that expression modulated by the trip-
ication-containing fragment from FeLV-945 was 3.6-fold
igher than that modulated by the analogous fragment from
eLV-A/61E (Athas et al., 1995b). These experiments sug-
est that the 21-bp triplication contributes genuine tran-
criptional enhancer function to the LTR that contains it, but
hey do not rule out a spacer function. In the present study,
dditional experiments were performed to examine a pos-
ible spacer function more directly. Specifically, the LTR of
A-945L was modified such that two copies of the tripli-
ated 21-bp sequence were replaced with 42 bp of random
equence. This virus is referred to as GA-TripR (Fig. 5).
lasmids (4 mg) encoding GA-945L or GA-TripR were intro-
uced by electroporation into parallel cultures of K-562
6 5
FIG. 5. (A)Diagram of the LTR of GA-945L and GA-TripR, illustrating
he number of repeats of enhancer, 21-bp sequence, and positioning of
hese elements relative to promoter (Pro). In the LTR of GA-TripR, two
opies of the 21-bp sequence have been replaced with 42-bp of
andom sequence (X). (B) Nucleotide sequence of the LTR of GA-945L
nd GA-TripR between conserved EcoRV and HincII restriction sites.
he triplicated 21-bp sequence in GA-945L is indicated as are se-
uence differences between GA-945L and GA-TripR.ells (4 3 10 cells at a density of 2 3 10 /ml). Culture gupernatants were harvested periodically thereafter for
easurement of reverse transcriptase activity. Genomic
NA also was isolated periodically to document stability of
he recombinant GA-TripR LTR. Analysis of reverse tran-
criptase activity in culture supernatants revealed a distinct
rowth advantage of nearly 2 orders of magnitude for GA-
45L compared to GA-TripR. This difference is evident be-
inning as early as Day 6 after infection (Fig. 6). Because
A-TripR replicates relatively poorly compared to GA-945L,
e anticipated a strong selective pressure in this experi-
ent for any mutant that might arise with increased repli-
ative potential. Thus to confirm the stability of the recom-
inant GA-TripR LTR during the course of the experiment,
he LTR was amplified by PCR from infected cells collected
t each time point (beginning at Day 6). Nucleotide se-
uence analysis of the products showed that the 42-bp
nsertion in the recombinant LTR is stable in culture for $3
eeks, although occasional point mutations are detected.
n continuous culture, however, mutants begin to accumu-
ate and, eventually, to predominate. It is interesting that two
uch mutants had precisely deleted the 42-bp random se-
uence and had accumulated two to three additional nu-
leotide substitutions (data not shown). The data shown in
ig. 6 represent collections up to Day 20, a period of time
uring which the 42-bp random substitution remains intact
n the GA-TripR LTR. The results of this experiment show
hat substitution of the nucleotide sequence of the 21-bp
riplication diminishes the ability of the FeLV-945 LTR to
irect virus replication, even though spacing and ste-
eospecific alignment were maintained. It is noteworthy that
he 42-bp random substitution essentially cripples virus
eplication (Fig. 6), whereas the simple deletion of two of
he 21-bp repeats diminishes replicative capacity much
ess drastically (Fig. 2). These data, along with our previ-
usly published findings (Athas et al., 1995a,b), indicate that
he 21-bp triplication does not perform solely a spacer
unction but that the sequence itself is important. These
indings are consistent with the precise conservation of the
equence and position of the triplication within the LTR of
ndependent isolates of FeLV-945. Were the selective pres-
ure solely to conserve appropriate spacing, precise con-
ervation of this particular repeat structure might not be
redicted.
The contribution of the specific nucleotide sequence
o the function of the 21-bp triplication is not yet known,
ut one possibility is that the sequence provides sites for
he specific binding of nuclear factors. To examine this
ossibility, electrophoretic mobility shift assays (EMSA)
ere performed using as probe a 96-bp AluI–HincII re-
triction fragment of the FeLV-945 LTR containing the
1-bp triplication. The results demonstrated the pres-
nce of specific protein–DNA complexes using nuclear
xtracts prepared from K-562 cells (Fig. 7). It is not yet
nown whether the specific binding of these proteins to
he 21-bp triplication contributes functionally to the
rowth advantage conferred by the FeLV-945 LTR. If so,
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467FUNCTION OF THE UNIQUE FeLV-945 LTRhen the selective advantage of retaining the specific
inding motif(s) may have contributed to the precise
onservation of the triplicated sequence.
An objective of the present study was to examine
elective pressures that shape natural retroviral infection
n an outbreeding mammalian host. The findings dem-
nstrate that the FeLV-945 LTR, identified uniquely in
on-B-cell non-T-cell feline lymphomas, confers a repli-
ative advantage on the virus that contains it, particularly
n primitive hematopoietic cells and in feline T-cells.
-562 has been useful in these studies as a model for
ultipotential hematopoietic cells. However, K-562 may
ot be generally representative of primitive hematopoi-
tic cells, and further, cells of human origin do not rep-
esent the natural host for FeLV. These limitations point
o the necessity of examining the growth advantage
onferred by FeLV-945 in vivo, as is planned for future
tudies. The FeLV-945 LTR contains unique sequence
lements that are precisely conserved among indepen-
ent isolates in a geographic cluster. The present find-
ngs indicate that the replicative advantage conferred by
he FeLV-945 LTR represents a selective pressure re-
ponsible for precise conservation of those sequence
lements.
MATERIALS AND METHODS
iruses and cell lines
Molecularly cloned, infectious proviral DNAs of FeLV
FIG. 6. Replication kinetics of GA-945L and GA-TripR in K-562 cells a
upernatants were collected at 3, 6, 10, 13, and 20 days after infecti
easured as described in the legend to Fig. 2. The data shown represe
f [3H]-TTP incorporated.sed in the study included FeLV-B/Gardner-Arnstein mMullins et al., 1981) and FeLV-A/61E (Donahue et al.,
988). Molecular clones of FeLV-945, FeLV-922, and the
1g945L recombinant were generated in previous stud-
es (Athas et al., 1995a,b). The FEA cell line, a continuous
ine of feline embryonic fibroblasts, was obtained from
ennifer Rojko, The Ohio State University, and was grown
n Dulbecco’s modified Eagle’s culture medium with 10%
etal calf serum (FCS). The human Jurkat T-cell line was
btained from Fayth Yoshimura, Wayne State University,
nd was grown in RPMI 1640 with 15% FCS. 3201 is an
eLV-negative thymic lymphoma-derived cell line of fe-
ine origin (Rojko et al., 1989) and was maintained in
PMI 1640 with 10% FCS. Other cell lines were obtained
rom American Type Culture Collection including the hu-
an malignant hematopoietic progenitor cell line, K-562
ATCC CCL 243), and the canine osteogenic sarcoma cell
ine, D-17 (ATCC CCL 183). These cell lines were grown
n RPMI 1640 with 10% FCS or Eagle’s minimal essential
ulture medium with 10% FCS, respectively.
onstruction of recombinant proviral clones
nd generation of infectious stocks
Recombinant FeLVs GA/945L, GA-922L, and GA-61EL
ere constructed from an infectious, molecular clone of
eLV-B/Gardner-Arnstein [FeLV-B/GA (Mullins et al.,
981)]. A 3-kb BamHI fragment containing the 39 terminus
f the proviral clone, including the full length of the
9LTR, was subcloned into a plasmid vector. This frag-
ured by reverse transcriptase activity in culture supernatants. Culture
ndicated. Reverse transcriptase activity in culture supernatants was
ean and standard error of triplicate experiments expressed as cpm/mls meas
on as i
nt the ment was modified through a series of stepwise diges-
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468 PRABHU, LOBELLE-RICH, AND LEVYions and ligations to construct recombinant LTRs. First,
he U3 region of the 39LTR of FeLV-B/GA was substituted
ith that of FeLV-945 (Athas et al., 1995a) between con-
erved EcoRV and KpnI restriction sites to yield the LTR
f GA-945L. That recombinant was further modified by
he substitution of an EcoRV–HincII fragment from the U3
egion of FeLV-922 (Athas et al., 1995a) or FeLV-A/61E
Donahue et al., 1988) to yield the LTRs of GA-922L and
A-61EL, respectively. The recombinant 3-kb BamHI
ragments then were introduced into full-length FeLV-
/GA to yield recombinant proviral clones bearing sub-
titutions in the 39 LTR. It is predicted that, by the action
f reverse transcriptase, the recombinant LTR would be
resent at both ends of proviral DNA generated after the
irst replication cycle. To generate infectious stocks, re-
ombinant proviral DNA (8 mg) was introduced into 1 3
07 D-17 cells by electroporation (Cell Porator Electropo-
ation System, Life Technologies, Inc.) at 1180 mF, 300 V,
ow V. Productive FeLV infection was monitored period-
cally thereafter using a commercially available ELISA for
FIG. 7. Electrophoretic mobility shift assays (Feghali et al., 1994)
erformed using as probe a radiolabeled 96-bp AluI-HincII fragment of
he FeLV-945 LTR containing the 21-bp triplication. Binding reactions
ontained radiolabeled probe (1 ng) and nuclear extract (3.5 mg) from
-562 cells. Included in the reactions as indicated was cold DNA probe
s specific competitor, or HindIII/HaeIII-digested bacteriophage l DNA
s nonspecific competitor, at 250-fold molar excess. Specific complex
ormation is seen in lanes 2 and 4.eLV p27gag in culture supernatants (Synbiotics Corp.). 4t 7 days after electroporation, supernatant was col-
ected from each culture, confirmed by ELISA to contain
eLV, aliquoted into 1-ml volumes, and frozen at 270°C.
otal cellular RNA was isolated from producer D17 cells
s previously described (Athas et al., 1995b). RNA (5 mg)
rom each infected culture was reverse transcribed using
00 U of RNase H2 Moloney leukemia virus reverse
ranscriptase (Superscript II; Life Technologies, Inc.) with
00 mM random hexamer primers for 30 min at room
emperature, followed by 1 h at 37°C and 5 min at 95°C.
eLV LTR sequences were amplified by PCR using prim-
rs LTR13 (59-AAAGACCCCCTACCCCAAAAACT) and
TR 14 (59-TGAGGCGGAAGGTCGGACTC) in a 100-ml re-
ction mixture containing 10% of the reverse transcrip-
ion reaction, 400 ng of each primer, 1.5 mM MgCl2, and
.2 mM of each deoxyribonucleotide triphosphate in a
aq polymerase reaction buffer provided by the manu-
acturer (Promega Corp.). An initial denaturation step at
8°C for 5 min was followed by addition of 5 units Taq
NA polymerase (Promega Corp.) and 35 cycles of de-
aturation at 94°C for 30 s, 57°C for 30 s, and 72°C for
min with a final extension for 15 min in a thermocycler
Robocycler 40; Stratagene). Amplification products were
xamined by agarose gel electrophoresis and cloned
nto the pGEM-T plasmid vector (Promega Corp.). Nucle-
tide sequence analysis was performed using the Se-
uenase enzyme (Amersham Life Sciences) as de-
cribed by the manufacturer.
The LTR of GA-TripR was generated from that of GA-
22L using spliced-overlap-extension (SOE) PCR (Horton
t al., 1990). SOE primers were designed to insert 42 bp
n the LTR of GA-922L, immediately following the single
opy of 21-bp sequence of interest. SOE primers used
ere GAX-b (59-AAGGTTCCGATCCGAACCCTAA-
TATAGCCTGCTGGCAGTGGCCTTG) and GAX-c
59-TTCGGATCGGAACCTTCCCTAACTCTAACTCTCCA-
GCTCCCCAGTT). Nucleotide sequence of the recom-
inant LTR was verified, and it was introduced into full-
ength proviral DNA to generate GA-TripR. For replication
ssays, proviral DNA encoding GA-TripR was introduced
y electroporation as described above into recipient
ells. Culture supernatants were collected periodically
hereafter, and genomic DNA was prepared as previ-
usly described (Bonham et al., 1987) from infected cells.
he FeLV LTR was amplified from genomic DNA using
TR13 and LTR14 in PCR reactions as described above.
mplification products were cloned into pGEM-T vector
nd subjected to nucleotide sequence analysis as de-
cribed above.
everse transcriptase assays
Tissue culture supernatants were clarified by filtration
hrough mStar LB filters (0.22 mm; Costar), and virus was
elleted by ultracentrifugation at 120,000 g for 90 min at
°C. The pellet was resuspended in 40 mM Tris, pH 8.1;
5
v
w
K
h
C
T
(
i
F
b
s
w
R
t
d
h
b
1
p
s
l
E
s
1
f
u
f
T
a
r
l
p
p
i
N
p
m
p
T
w
v
b
o
c
t
i
A
C
A
A
A
B
B
B
C
C
C
C
C
D
D
D
D
F
F
F
G
H
469FUNCTION OF THE UNIQUE FeLV-945 LTR0 mM KCl; 20 mM dithiothreitol; and 0.2% NP-40. The
irus suspension, or dilutions of it in the same buffer,
as added 1:1 to a solution of 40 mM Tris, pH 8.1; 50 mM
Cl; 2 mM MnCl2; 0.04 mg/ml poly(A)–oligo(dT)15 (Boe-
ringer-Mannheim); and 100 mCi/ml methyl-[3H]-TTP (20
i/mmol; NEN-DuPont) and incubated at 37°C for 1 h.
he entire reaction was spotted onto a DE-81 filter disk
Whatman), air-dried, and washed four times, 5 min each,
n 0.5 M Na2HPO4, followed by 5 min in 95% ethanol.
ilters were dried and incorporated [3H]-TTP quantified
y liquid scintillation counting in ScintiVerse E (Fisher). A
eries of at least three dilutions of each virus suspension
ere assayed to establish the linearity of the reaction.
NA isolation and Northern blot analysis
Total cellular RNA was isolated by guanidinium iso-
hiocyanate extraction and cesium chloride density gra-
ient ultracentrifugation as described previously (Bon-
am et al., 1987). RNA (5 mg) was subjected to Northern
lot analysis as previously described (Athas et al.,
995b). Filters were hybridized to an exogenous FeLV U3
robe to identify viral RNA (Casey et al., 1981) and sub-
equently to a probe for b-actin to demonstrate uniform
oading of the gel.
lectrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared from K-562 cells using
tandard procedures (Dignam et al., 1983; Feghali et al.,
994). Electrophoretic mobility shift assays were per-
ormed as previously described (Feghali et al., 1994)
sing as probe a 96-bp AluI–HincII restriction fragment
rom the FeLV-945 LTR containing the 21-bp triplication.
he restriction fragment had been previously cloned into
plasmid vector; thus for use in this assay, it was
eleased by digestion with EcoRI and HindIII and radio-
abeled by end-filling using the Klenow fragment of DNA
olymerase. Binding reactions included radiolabeled
robe (1 ng) and nuclear extract (3.5 mg) from K-562 cells
n a 15-ml reaction containing 10 mM Tris, pH 7.5;75 mM
aCl; 10 mM EDTA;7% glycerol; 1 mM DTT; and 2 mg
oly(dI-dC). The mixtures were incubated at 30°C for 30
in and then resolved by 6% polyacrylamide gel electro-
horesis in 0.253 TBE buffer (13 TBE buffer is 89 mM
ris base, 89 mM boric acid, and 2 mM EDTA). Gels then
ere dried at 80°C and exposed to radiographic film for
arying periods of time. In some reactions, nonradiola-
eled DNA probe was included as a specific competitor
r HindIII/HaeIII-digested bacteriophage l DNA was in-
luded as nonspecific competitor. In that case, the reac-
ants were incubated with competitor DNA for 20 min on
ce before addition of the radiolabeled probe.
ACKNOWLEDGMENTS
This work was supported by Grant RPG-94-012-04-VM from the
merican Cancer Society and by Development Funds of the Tulane
ancer Center.REFERENCES
thas, G. B., Choi, B., Prabhu, S., Lobelle-Rich, P. A., and Levy, L. S.
(1995a). Genetic determinants of feline leukemia virus-induced mul-
ticentric lymphomas. Virology 214(2), 431–438.
thas, G. B., Lobelle-Rich, P., and Levy, L. S. (1995b). Function of a
unique sequence motif in the long terminal repeat of feline leukemia
virus isolated from an unusual set of naturally occurring tumors.
J. Virol. 69(6), 3324–3332.
thas, G. B., Starkey, C. R., and Levy, L. S. (1994). Retroviral determi-
nants of leukemogenesis. Crit. Rev. Oncog. 5(2–3), 169–199.
onham, L., Lobelle-Rich, P. A., Henderson, L. A., and Levy, L. S. (1987).
Transforming potential of a myc-containing variant of feline leukemia
virus in vitro in early-passage feline cells. J. Virol. 61(10), 3072–3081.
oomer, S., Gasper, P., Whalen, L. R., and Overbaugh, J. (1994). Isolation
of a novel subgroup B feline leukemia virus from a cat infected with
FeLV-A. Virology 204(2), 805–810.
urger, S. R., Zutter, M. M., Sturgill-Koszycki, S., and Santoro, S. A.
(1992). Induced cell surface expression of functional alpha2beta1
integrin during megakaryocytic differentiation of K562 leukemic cells.
Exp. Cell Res. 202, 28–35.
asey, J. W., Roach, A., Mullins, J. I., Burck, K. B., Nicolson, M. O.,
Gardner, M. B., and Davidson, N. (1981). The U3 portion of feline
leukemia virus DNA identifies horizontally acquired proviruses in
leukemic cats. Proc. Natl. Acad. Sci. USA 78(12), 7778–7782.
hen, H., and Yoshimura, F. K. (1994). Identification of a region of a
murine leukemia virus long terminal repeat with novel transcriptional
regulatory activities. J. Virol. 68(5), 3308–3316.
hen, H., and Yoshimura, F. K. (1998). Spacing between the enhancer
and promoter of the long terminal repeat of a murine leukaemia
retrovirus is required for transcriptional activation in T cells. J. Gen.
Virol. 79(5), 1101–1104.
offin, J. M. (1992). Genetic diversity and evolution of retroviruses. Curr.
Top. Microbiol. Immunol. 176, 143–164.
ourchamp, F., Suppo, C., Fromont, E., and Bouloux, C. (1997). Dynam-
ics of two feline retroviruses (FIV and FeLV) within one population of
cats. Proc. R. Soc. Lond. B Biol. Sci. 264(1383), 785–794.
iFronzo, N. L., and Holland, C. A. (1999). Sequence-specific and/or
stereospecific constraints of the U3 enhancer elements of MCF
247-W are important for pathogenicity. J. Virol. 73(1), 234–241.
ignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983). Accurate
transcription initiation by RNA polymerase II in a soluble extract from
isolated mammalian nuclei. Nucleic Acids Res. 11(5), 1475–1489.
omingo, E., Martinez-Salas, E., Sobrino, F., de la Torre, J. C., Portela, A.,
Ortin, J., Lopez-Galindez, C., Perez-Brena, P., Villanueva, N., Najera,
R., et al. (1985). The quasispecies (extremely heterogeneous) nature
of viral RNA genome populations: Biological relevance—a review.
Gene 40(1), 1–8.
onahue, P. R., Hoover, E. A., Beltz, G. A., Riedel, N., Hirsch, V. M.,
Overbaugh, J., and Mullins, J. I. (1988). Strong sequence conservation
among horizontally transmissible, minimally pathogenic feline leuke-
mia viruses. J. Virol. 62(3), 722–731.
eghali, C. A., Bost, K. L., Boulware, D. W., and Levy, L. S. (1994). Control
of IL-6 expression and response in fibroblasts from patients with
systemic sclerosis. Autoimmunity 17, 309–318.
romont, E., Pontier, D., and Langlais, M. (1998). Dynamics of a feline
retrovirus (FeLV) in host populations with variable spatial structure.
Proc. R. Soc. Lond. B Biol. Sci. 265(1401), 1097–1104.
ulton, R., Plumb, M., Shield, L., and Neil, J. C. (1990). Structural diversity
and nuclear protein binding sites in the long terminal repeats of
feline leukemia virus. J. Virol. 64(4), 1675–1682.
olemis, E. A., Speck, N. A., and Hopkins, N. (1990). Alignment of U3
region sequences of mammalian type C retroviruses: Identification of
highly conserved motifs and implications for enhancer design. J. Vi-
rol. 64, 534–542.
oover, E. A., and Mullins, J. I. (1991). Feline leukemia virus infection
and diseases. J. Am. Vet. Med. Assoc. 199(10), 1287–1297.
HK
L
L
M
M
M
M
N
N
P
P
R
R
R
R
R
T
T
Y
470 PRABHU, LOBELLE-RICH, AND LEVYorton, R. M., Cai, Z. L., Ho, S. N., and Pease, L. R. (1990). Gene splicing
by overlap extension: Tailor-made genes using the polymerase chain
reaction. BioTechniques 8(5), 528–535.
atz, R. A., and Skalka, A. M. (1990). Generation of diversity in retrovi-
ruses. Annu. Rev. Genet. 24, 409–445.
evesque, K. S., Bonham, L., and Levy, L. S. (1990). flvi-1, a common
integration domain of feline leukemia virus in naturally occurring
lymphomas of a particular type. J. Virol. 64(7), 3455–3462.
ozzio, B. B., Lozzio, C. B., Bamberger, E. G., and Feliu, A. S. (1981). A
multipotential leukemia cell line (K562) of human origin. Proc. Soc.
Exp. Biol. Med. 166, 546–550.
ansky, L. M. (1998). Retrovirus mutation rates and their role in genetic
variation. J. Gen. Virol. 79(6), 1337–1345.
atsumoto, Y., Momoi, Y., Watari, T., Goitsuka, R., Tsujimoto, H., and
Hasegawa, A. (1992). Detection of enhancer repeats in the long
terminal repeats of feline leukemia viruses from cats with spontane-
ous neoplastic and nonneoplastic diseases. Virology 189(2), 745–
749.
cDougall, A. S., Terry, A., Tzavaras, T., Cheney, C., Rojko, J., and Neil,
J. C. (1994). Defective endogenous proviruses are expressed in feline
lymphoid cells: Evidence for a role in natural resistance to subgroup
B feline leukemia viruses. J. Virol. 68(4), 2151–2160.
ullins, J. I., Casey, J. W., Nicolson, M. O., Burck, K. B., and Davidson,
N. (1981). Sequence arrangement and biological activity of cloned
feline leukemia virus proviruses from a virus-productive human cell
line. J. Virol. 38(2), 688–703.
eil, J. C., Fulton, R., Rigby, M., and Stewart, M. (1991). Feline leukaemia
virus: Generation of pathogenic and oncogenic variants. Curr. Top.
Microbiol. Immunol. 171, 67–93.
ishigaki, K., Endo, Y., Matsumoto, Y., Watari, T., Goitsuka, R., Tsujimoto,
H., and Hasegata, A. (1997). Regulation of gene expression directed
by the long terminal repeats of feline leukemia viruses. Leukemia 11,
Suppl. 3, 189–192.antginis, J., Beaty, R. M., Levy, L. S., and Lenz, J. (1997). The feline
leukemia virus long terminal repeat contains a potent genetic deter-
minant of T-cell lymphomagenicity. J. Virol. 71(12), 9786–9791.
lumb, M., Fulton, R., Breimer, L., Stewart, M., Willison, K., and Neil, J. C.
(1991). Nuclear factor 1 activates the feline leukemia virus long
terminal repeat but is posttranscriptionally down-regulated in leuke-
mia cell lines. J. Virol. 65(4), 1991–1999.
ezanka, L. J., Rojko, J. L., and Neil, J. C. (1992). Feline leukemia virus:
Pathogenesis of neoplastic disease. Cancer Invest. 10(5), 371–389.
hodes, D., and Klug, A. (1980). Helical periodicity of DNA determined
by enzyme digestion. Nature 286(5773), 573–578.
ohn, J. L., and Overbaugh, J. (1995). In vivo selection of long terminal
repeat alterations in feline leukemia virus-induced thymic lympho-
mas. Virology 206(1), 661–665.
ojko, J. L., Kociba, G. J., Abkowitz, J. L., Hamilton, K. L., Hardy, W. D., Jr.,
Ihle, J. N., and O’Brien, S. J. (1989). Feline lymphomas: Immunological
and cytochemical characterization. Cancer Res. 49(2), 345–351.
oy-Burman, P. (1996). Endogenous env elements: Partners in genera-
tion of pathogenic feline leukemia viruses. Virus Genes 11(2–3),
147–161.
satsanis, C., Fulton, R., Nishigaki, K., Tsujimoto, H., Levy, L., Terry, A.,
Spandidos, D., Onions, D., and Neil, J. C. (1994). Genetic determi-
nants of feline leukemia virus-induced lymphoid tumors: Patterns of
proviral insertion and gene rearrangement. J. Virol. 68(12), 8296–
8303.
ullius, T. D., and Dombroski, B. A. (1985). Iron(II) EDTA used to mea-
sure the helical twist along any DNA molecule. Science 230(4726),
679–681.
oshimura, F. K., Cankovic, M., Smeltz, R., and Ibrahim, S. (1997).
Identification of nucleotide sequences that regulate transcription of
the MCF13 murine leukemia virus long terminal repeat in activated T
cells. J. Virol. 71(3), 2572–2576.
